Analysing non-compliance in clinical trials: Ethical imperative or mission impossible?

Statistics in Medicine

Volumn 15, Issue 24, 1996, Pages 2813-2826

  Goetghebeur, Els J T ^a,b   Shapiro, Stanley H ^c  

^a HASSELT UNIVERSITY   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONFERENCE PAPER; ETHICS; HUMAN; PATIENT COMPLIANCE; RANDOMIZATION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

DATA INTERPRETATION, STATISTICAL; ETHICS, MEDICAL; HUMANS; MODELS, STATISTICAL; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0030452056     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19961230)15:24<2813::AID-SIM366>3.0.CO;2-U     Document Type: Conference Paper

References (28)

1. Cramer, J. A. and Spilker, B. (eds). Non-compliance in Clinical Trials, Raven Press, New York, 1992.
2. Efron, B. and Feldman, D. 'Compliance as an explanatory variable in clinical trials', Journal of the American Statistical Association, 86, 9-26 (1991).
3. Guillebaud, J. 'What to do when you miss a pill (or two or three?)', British Medical Journal, 307, 617 (1993).
4. Lasagna, L. 'Noncompliance data and clinical outcomes: impact on health care', Primary Cardiology Supplement, 1, 36-39 (1992).
5. Psaty, B. M., Koepsell, T. D., Wagner, E. H., LoGerfo, J. P. and Inui, T. S. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers', Journal of the American Medical Association, 263, 1653-1657 (1990).
6. Krall, R. L. 'Interaction of compliance and patient safety', in Cramer, J. A. and Spilker, B. (eds), Patient Compliance in Medical Practice and Clinical Trials, Raven Press, 1991, p. 22.
7. Temple, R. 'Dose response and registration of new drugs', in Lasagna, L., Erill, S. and Naranjo, C. A. (eds), Dose-response Relationships in Clinical Pharmacology, Elsevier, Amsterdam, 1989, pp. 145-167.
8. QUESTRAN (cholestyramine). Physicians Desk Reference, Medical Economics Co., Oradell, New Jersey, 1990.
9. Levine, R. J. Ethics and Regulation of Clinical Research, Yale University Press, 1986.
10. Holland, P. W. 'Statistics and causal inference', Journal of the American Statistical Association, 81, 945-970 (1986).
11. Heitjan, D. F. and Rubin, D. B., 'Ignorability and coarse data', Annals of Statistics, 19, 2244-2253 (1991).
12. Heyting, A., Tolboom, J. T. B. M. and Essers, J. G. A. 'Statistical handling of drop-outs in longitudinal clinical trials', Statistics in Medicine, 11, 2043-2061 (1992).
13. Diggle, P. and Kenward, M. 'Informative drop-out in longitudinal data analysis (with discussion)', Applied Statistics, 43, 49-93 (1994).
14. Molenberghs, G., Kenward, M. and Lesaffre, E. 'Informative drop-out in ordinal longitudinal data', Submitted.
15. Rubin, D. B. 'Inference and missing data', Biometrika, 63, 581-592 (1976).
16. Harris, R. I. 'Letter on "Statistical handling of drop-outs in longitudinal clinical trials" by A. Heyting, J. T. B. M. Tolboom, and J. G. A. Essers; with response from the authors', Statistics in Medicine, 12, 2248-2250 (1993).
17. Rosenbaum, P. R. and Rubin, D. B. The central role of the propensity score in observational studies for causal effects', Biometrika, 70, 41-55 (1983).
18. Robins, J. M., Mark, S. D. and Newey, W. K. 'Estimating exposure effects by modelling the expectation of exposure conditional on confounders', Biometrics, 48, 479-495 (1992).
19. Robins, J. M. 'Estimation of the time-dependent accelerated failure time model in the presence of confounding factors', Biometrika, 79, 321-334 (1992).
20. Robins, J. M. 'The control of confounding by intermediate variables', Statistics in Medicine, 8, 679-701 (1989).
21. Robins, J. M., Blevins, D., Ritter, G. and Wulfsohn, M. 'G-estimation of the effect of prophylaxis therapy for pneumocystis carinii pneumonia on the survival of aids patients', Epidemiology, 3, 319-336 (1992).
22. Robins, J. M. and Tsiatis, A. A. 'Correcting for non-compliance in randomized clinical trials using rank preserving structural failure time models', Communications in Statistics - Theory and Methods, 20, 2609-2631 (1991).
23. Oakes, D. O., Moss, A. J., Fleiss, J. L., Bigger, J. T., Therneau, T., Eberly, S. W., McDermot, M. P., Mantunga, A., Carleen, E., Benhorin, J. and The Multicenter Diltiazim Post-infarction Trial Research Group. 'Use of compliance measures in an analysis of the effect of diltiazim on mortality and reinfarction after myocardial infarction', Journal of the American Statistical Association, 88, 44-49 (1993).
24. Goetghebeur, E. and Pocock, S. 'Statistical issues in allowing for non-compliance and withdrawal', Drug Information Journal, 27, 837-845 (1993).
25. Hastie, T. and Tibshirani, R. 'Varying-coefficient models (with discussion)', Journal of the Royal Statistical Society, Series B, 55, 757-796 (1993).
26. Dawid, A. P. 'Conditional independence in statistical theory', Journal of the Royal Statistical Society, Series B, 41, 1-31 (1979).
27. Robins, J. M. 'Correcting for non-compliance in randomized trials using structural nested mean models', Communications in Statistics - Theory and Methods, 23, 2379-2412 (1994).
28. Lee, J., Ellenberg, J., Hirtz, D. and Nelson, K. 'Analysis of clinical trials by treatment actually received: is it really an option?', Statistics in Medicine, 10, 1595-1605 (1991).